{"filing":{"accession_number":"0001213900-26-101635","cik":"0001723069","ticker":"TLSA","company_name":"Tiziana Life Sciences Ltd","form":"6-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"ea0306087-6k_tiziana.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1723069/000121390026101635/ea0306087-6k_tiziana.htm"},"events":[{"id":33852,"run_id":31155,"accession_number":"0001213900-26-101635","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces completion of the last patient visit in the Phase 2a INFORM-MS clinical trial of intranasal foralumab for Secondary Progressive Multiple Sclerosis. The company expects to lock the database and announce topline data in October. This is a material clinical development milestone for a clinical-stage biotech company's lead candidate, affecting investor assessment of pipeline progress and near-term catalysts, but it is not a discrete event type (earnings, M\u0026A, executive change, etc.) — it is an operational/clinical milestone best classified as operational_other.","company_name":"Tiziana Life Sciences Ltd","ticker":"TLSA","filing_date":"2026-09-21","form":"6-K","submitted_at":null,"items":[{"id":37413,"accession_number":"0001213900-26-101635","item_number":"EX-99.1","item_title":"ea030608701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of the last patient visit in the Phase 2a INFORM-MS clinical trial of intranasal foralumab for Secondary Progressive Multiple Sclerosis. The company expects to lock the database and announce topline data in October. This is a material clinical development milestone for a clinical-stage biotech company's lead candidate, affecting investor assessment of pipeline progress and near-term catalysts, but it is not a discrete event type (earnings, M\u0026A, executive change, etc.) — it is an operational/clinical milestone best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:01:21.949136+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37413,"accession_number":"0001213900-26-101635","item_number":"EX-99.1","item_title":"ea030608701ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces completion of the last patient visit in the Phase 2a INFORM-MS clinical trial of intranasal foralumab for Secondary Progressive Multiple Sclerosis. The company expects to lock the database and announce topline data in October. This is a material clinical development milestone for a clinical-stage biotech company's lead candidate, affecting investor assessment of pipeline progress and near-term catalysts, but it is not a discrete event type (earnings, M\u0026A, executive change, etc.) — it is an operational/clinical milestone best classified as operational_other.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-21T11:01:21.949136+00:00","company_name":"Tiziana Life Sciences Ltd","ticker":"TLSA","filing_date":"2026-09-21"}]}